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Abstract: With the availability of new technologies, the number of subjects undergoing medical
and cosmetic interventions is increasing. Many procedures (e.g., ablative fractional laser treatment)
resulting in superficial/minor wounds require appropriate aftercare to prevent complications in
wound healing and poor cosmetic outcome. We review the published evidence of the usefulness
of topical dexpanthenol in postprocedure wound healing and the associated mechanisms of action
at the molecular level. A search in the PubMed and Embase databases was performed to query the
terms dexpanthenol, panthenol, superficial wound, minor wound, wound healing, skin repair, and
postprocedure. Search results were categorized as clinical trials and in vitro studies. In vitro and
clinical studies provided evidence that topically applied dexpanthenol promotes superficial and
postprocedure wound healing. Latest findings confirmed that dexpanthenol upregulates genes that
are critical for the healing process. The gene expression data are of clinical relevance as evidenced by
prospective clinical studies indicating that topical dexpanthenol accelerates wound healing with rapid
re-epithelialization and restoration of skin barrier function following skin injury. It can therefore be
inferred that topical dexpanthenol represents an appropriate and state-of-the-art treatment option for
superficial postprocedure wounds, especially when applied early after the superficial skin damage.
Keywords: wound healing; dexpanthenol; postprocedure; minor wounds
1. Introduction
Many medical and cosmetic interventions, such as ablative laser treatment, dermabrasion,
microneedling, or tattooing, result in superficial/minor wounds; this affects the integrity of the
epidermis and requires postprocedural wound care to assure a proper healing process of the damaged
skin [1–3]. Topical compounds that support all three phases of wound healing (inflammation,
proliferation, and remodeling) are considered particularly useful for the treatment of minor and
superficial wounds [4]. Recently, it has been suggested that dexpanthenol exhibits activity across all
three wound healing phases [4].
Dexpanthenol is well absorbed when applied topically to the skin and rapidly converted to
pantothenic acid [5–7]. The latter is a coenzyme A constituent and essential for the physiological function
of epithelia [8,9]. Dexpanthenol supports skin regeneration by enhancing epidermal differentiation
and facilitates wound healing [9–11]; it also showed activity in the prevention of biofilm formation and
has anti-inflammatory effects [12,13]. Furthermore, dexpanthenol acts as a moisturizer and skin barrier
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enhancer [14–17]. In dry skin conditions, it compensates for reduced hydration by increasing water
content and by beneficially influencing the molecular mobility of the stratum corneum lipid lamellae and
proteins [9,11,18]. These features triggered the development of various topical dexpanthenol-containing
galenical formulations which are widely used in the dermatological field. Topical dexpanthenol has
also been recommended for the treatment of minor and superficial wounds [9].
In this paper, we review the usefulness of topical dexpanthenol in postprocedure wound healing
and the associated mechanisms of action at the molecular level.
2. Search Strategy
A systematic literature search was performed in the PubMed and Embase databases. Various
combinations of the following terms were queried: dexpanthenol, panthenol, superficial wound,
minor wound, wound healing, skin repair, postprocedure. In addition, references cited in related
publications were followed up. Articles for this review were restricted to clinical trials (in vivo data)
and in vitro studies. There were no date or language criteria for inclusion in this paper. In total,
the search identified 33 publications. Of these, 8 articles were of relevance for assessing the usefulness
of topical dexpanthenol in wound healing after medical and cosmetic interventions. The most frequent
reasons for article rejection were studies involving animals and trials investigating dexpanthenol
combination products.
3. Types of Wounds and Process of Repair
3.1. Wounds
Wounds can be classified as acute or chronic. Chronic wounds frequently occur in patients with
underlying diseases (e.g., diabetes or malignancies), are difficult to heal, and need special wound
management [19]. Acute wounds are most frequently caused by mechanical injuries but can also be
caused by burns or chemical harms [19]. The management of this type of wound is performed on
an individual basis and varies depending on the wound location and characteristics [20,21]. Acute
wounds may involve deeper structures of the dermis (including blood vessels, sweat glands, and/or
hair follicles) which are referred to as partial-thickness wounds. In the case of full-thickness wounds,
the subcutaneous fat or deeper tissues are additionally damaged [19,22]. In superficial wounds of the
skin (e.g., abrasions or superficial thermal wounds), the epidermis is affected [19]; superficial parts of
the dermis may be involved as well [22]. The term “minor wounds” usually describes small acute
cutaneous wounds, such as small cuts, scraps, fissures, or superficial incisions [22,23]. If bleeding
from minor wounds occurs, it can be stopped by putting pressure on the affected skin area or by using
dressings or skin tapes. Frequently, subjects treat superficial/minor everyday wounds themselves [24].
Superficial and minor wounds also occur following scheduled medical or cosmetic interventions,
such as ablative laser treatment of the skin (ablative laser skin resurfacing), dermabrasion, or the
tattooing procedure. During ablative laser therapy, the epidermis and parts of the dermis are removed
while non-ablative laser therapy leaves the skin surface undamaged [25,26]. A more recently applied
laser technique for skin treatments is fractional laser. Fractional lasers deliver the laser light in fractions
onto the skin surface and work either ablative or non-ablative [25,27]. Following ablative fractional
laser treatment, ablation zones (holes) are present in the epidermis and superficial dermis that are
surrounded by areas with intact skin surface [25,28]. In response to all these laser therapies, overheating
of epidermal and dermal compartments may occur which can cause thermal injury, especially after
CO2 laser irradiation [25,26,29].
The use of ablative lasers has been established as an effective technique to treat aged or
sun-damaged skin (e.g., actinic keratosis [30]). Frequently used lasers are CO2 and erbium-doped
yttrium aluminum garnet (Er:YAG) lasers [26]. For ablative fractional laser treatments, CO2 and
Er:YAG lasers are both applied, but the CO2 laser is generally preferred by dermatologists and has
become the method of choice in the therapy of photo-damaged skin [2,25,31].
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During a tattooing session, the tattoo needle punches repeatedly through the epidermis and
introduces pigments and dyes into the dermis; generally, the skin injuries are confined to the epidermis
and upper parts of the dermis depending on the experience of the tattooing person [32–34]. In parallel
to the increasing popularity of tattoos, the number of subjects who would like to get them removed
has also increased. For tattoo removal, laser treatment has become the gold standard [35,36]. The laser
selection depends on the tattoo colors and skin type, but the Q-switched YAG laser is considered
the standard laser therapy for tattoo removal [36,37]. Particularly for multicolored tattoos, ablative
fractional laser treatment (alone or in combination with other laser techniques) might be an alternative
option for effective tattoo removal [25,35].
Selective absorption of the laser light by the pigments results in fragmented tattoo particles which
allows transportation of the tinier fragments away from the skin via phagocytosis [36,38]. Tattoo
removal by lasers typically causes postprocedure open wounds on the treated skin due to the high
energy of the intense light pulses [38].
3.2. Wound Healing
All the aforementioned superficial or minor wounds require proper care to achieve a scar-free
wound healing or healing with a subtle scar only [22,39]. Although the skin injuries are minor in nature,
a proper and early wound care is advised to accelerate re-epithelization and thus minimize infection
risk and the formation of a hypertrophic scar [24]. Even if the injury occurred in the context of a
scheduled and controlled intervention with adequate hygiene measures, there is the necessity of topical
postprocedure wound care; it has been shown that effective postprocedure wound healing reduces
the incidence of postprocedure complications which ensures a satisfying cosmetic outcome as much
as possible [40,41]. An undisturbed wound healing results in a better cosmetic result. Consequently,
an appropriate postprocedure topical wound treatment has been recommended after ablative laser
treatments of the skin [2]. Likewise, following the tattooing procedure, it has been emphasized that
aftercare is actually wound care [42]. If performed inadequately, there is an increased risk of infection
and wound healing may be impaired. In addition, it could have a negative impact on the aesthetic
outcome of the tattoo procedure [1]. Similarly, in case the tattoo will be removed by laser techniques,
the application of ointments and protective dressings are recommended [35].
Wound healing is a dynamic process and represents the body’s response to injury [43–45]. The aim
of wound healing after minor injury is to restore skin integrity in a timely fashion with an appearance
and functionality which ideally is indistinguishable from the preinjury skin [4]. Acute superficial/minor
cutaneous wounds usually heal within three weeks after which barrier function and normal skin
structure are fully restored, although formation of scars may occur [22,46]. Traditionally, the wound
healing process has been divided in three sequential phases: inflammation, proliferation, and matrix
deposition (remodeling) [47,48]. Recent research on the different steps involved in wound healing
suggests that these three phases of wound repair overlap with multiple actions running in parallel [4].
A three-dimensional (3D) human full-thickness skin model was developed to study the
morphological and molecular alterations during the healing process of epidermal wounds [3,49,50].
The 3D skin model consists of epidermal and dermal layers comprising a functional stratum corneum,
basal layer, and basal membrane [3,51]. Although this in vitro model cannot fully mimic the complex
in vivo conditions, it is able to provide insight into the histological and molecular effects induced
by superficial injuries [3]. By means of the 3D skin model, the histological changes and shifts in
gene expression related to epidermal differentiation, inflammation, and remodeling were defined
that occur after epidermal wounding caused by ablative fractional Er:YAG laser, ablative fractional
CO2 laser, or microneedling [3,50,51]. After microneedling, genes like COL3A1, COL8A1, and
TIMP3 were upregulated whereas pro-inflammatory cytokines were downregulated [3]. Following
ablative fractional Er:YAG laser treatment, there was an increased mRNA expression of matrix
metalloproteinases and their inhibitors (e.g., MMPs), chemokines (e.g., CXCL1 and CXCL2), and
cytokines (e.g., IL6, IL8, and IL24), whereas mRNA expression of epidermal differentiation markers
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(e.g., keratin-associated protein 4, filaggrin 1, and filaggrin 2) was reduced [51]. The findings allow
studying the pharmacological effects of topical treatments in these settings as a substitute for in vivo
studies [51]. Data gathered with the 3D skin model showed good correlations with data retrieved
from human skin in vivo studies [49,52,53]. Both laser-irradiated human 3D skin cultured in calcium
pantothenate-containing medium and samples of dexpanthenol-treated injured human skin showed
a decreased expression of S100A7 (psoriasin), a protein detected in epidermal layers of acute and
chronic wounds [49,53]. Recently, also a human full-thickness 3D non-keratinized mucous membrane
model has been established [54]. It mimics two layers of the mucous membrane (stratified squamous
epithelium and lamina propria) and allows studying effects of topical agents on mucosa histology and
gene expression.
4. Dexpanthenol in Wound Healing
Wound management has to simultaneously address all three phases of wound healing and should
comprise protection from infection and free radicals, modulation of inflammation, support of cell
proliferation, and acceleration of migration [4]. Baron et al. recently suggested that dexpanthenol
fulfills these criteria (with the caveat that for infection protection a mild antiseptic has to be added),
thereby exhibiting activity across all three wound healing phases [4]. In fact, dexpanthenol was shown
to assist the different steps of wound-healing in various in vitro and in vivo studies [4,9]. Specifically,
topically applied dexpanthenol-containing formulations facilitated wound healing in in vivo models
of superficial skin [55–57] as well as in women with nipple cracks and fissures [58–60], and were used
as reference preparation in trials investigating new developments for the care of minor everyday
wounds [61].
4.1. Role of Dexpanthenol on Postprocedure Wound Healing—In Vitro Data
Marquardt and colleagues studied the effects of dexpanthenol on wound healing and gene
regulation by employing the 3D skin model [49]. Skin equivalents were irradiated with a non-sequential
fractional ultrapulsed CO2 laser. Subsequently, the injured skin equivalents were treated for three days
with various 5% dexpanthenol-containing ointments or petroleum jelly (vaseline). Laser irradiated
untreated 3D skin served as control. Histological, microarray, and quantitative reverse transcription
polymerase chain reaction (qRT-PCR) analyses were performed at different time points. Topical
treatment of skin wounds with 5% dexpanthenol formulations enhanced wound closure compared
with the CO2 laser-irradiated untreated control or wounds treated with petroleum jelly. Culture
analyses confirmed that the observed favorable effect was caused by dexpanthenol and not by
the ointment base. Culturing laser-irradiated skin equivalents in calcium pantothenate-containing
medium resulted in different molecular effects. Among them, gene expressions of interleukin
(IL)-1α, a proinflammatory cytokine that acts across the three wound healing phases [4], and matrix
metalloproteinase 3 (MMP3), a regulator of wound healing [62], were upregulated. Moreover, three
days after skin injury, immunofluorescence studies showed an upregulated Ki67 protein expression
in laser-irradiated 3D skin cultured with calcium pantothenate compared to control. The results are
noteworthy because, without treatment, the expression of IL-1α and MMP3 is actually downregulated
following fractional ultrapulsed CO2 laser irradiation [50]. The upregulation of the Ki67 protein,
a proliferation marker, is in accordance with an earlier study which used an in vitro model of
artificially wounded monolayers (scrape wounds) [52]. There, dermal fibroblasts, incubated with
calcium pantothenate (20 µg/mL), revealed an enhanced proliferation compared with untreated cells,
suggesting a stimulatory effect of pantothenate on the proliferation of dermal fibroblasts. Among
others, genes coding for IL-6 and IL-8 were upregulated by calcium pantothenate. Both cytokines are
important for the healing of human dermal wounds [9,63].
In another study, Schmitt and coworkers investigated the molecular effects of dexpanthenol
on mucosal wound healing after introducing standardized lesions with a non-sequential fractional
ultrapulsed CO2 laser [54]. For that purpose, the novel human full-thickness 3D non-keratinized
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mucous membrane in vitro model was employed. Immediately after laser injury, models were topically
treated with an ointment containing 5% dexpanthenol or placebo for 5 days. The culture medium was
free of dexpanthenol or other ingredients known to increase proliferation. Histological examinations led
to the conclusion that treatment with the dexpanthenol-ointment enhanced wound closure compared
with placebo. Gene expression analyses revealed that topical application of dexpanthenol was
associated with a >1.5-fold upregulation of various genes involved in wound healing, such as the
CXCL10 gene, mucin protein family genes, and the retinoic acid receptor responder protein 1 gene
(RARRES1) (Figure 1).
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Figure 1. Gene expression profiling in 3D mucous membrane models after laser injury and treatment
with a dexpanthenol-containing ointment in comparison with the placebo-treated control. (a) 3D
mucous membrane models were harvested 3 days after laser treatment (100 mJ/cm2), and gene
expression was measure using the Affymetrix® Gene Chip Human Exon 2.0 ST microarray. Results
of 3 experiments were pooled. (b) TaqMan real-time polymerase chain reaction (qRT-PCR) analysis
of select d genes on day 3 after treatment. M n values with standard error of the mean (SEM) of 3
indep ndent xperiments performed in duplicate are shown. From Ref. [54] with kind p rmission fr m
S. Karger AG (www.karger.com/SPP).
4.2. Role of Dexpanthenol on Postprocedure Wound Healing—In Vivo Data
Girard et al. conducted a double-blind, intra-individual comparative trial that studied the
postprocedure wound healing effects of an ointment containing 5% dexpanthenol [64]. In total,
35 patients received an autologous skin graft because of burns. For 14 days, the dexpanthenol-containing
formulation or vehicle was topically applied to the mesh graft donor sites (i.e., to sites from which skin
grafts were removed). These superficial wounds tended to heal more rapidly at the sites treated with
dexpanthenol than at the skin areas treated with vehicle as assessed clinically and by measurements of
microcirculation, temperature, and biomechanical properties. During the second week of the study,
the skin areas topically treated with dexpanthenol were more hydrated than those treated with vehicle
(p = 0.05) based on clinical scores. Moreover, pruritus related to wound healing resolved sooner
(p = 0.06).
A randomized, double-blind study in healthy subjects investigated the modulation of gene
expression by dexpanthenol in previously injured punch skin biopsies [53]. In each subject, two minor
wounds were introduced by injuring the skin with 4 mm punch biopsies. One wound was topically
treated with a 5% dexpanthenol-containing ointment and one wound with placebo. Eight-millimeter
punch biopsies of dexpanthenol- and placebo-treated skin areas were taken up to 144 h following
treatment initiation. Subsequently, the biopsy material was analyzed to compare the postprocedure
gene expression profile of dexpanthenol-treated wounds in comparison with placebo-treated wounds.
In specimens treated with dexpanthenol, upregulation of genes involved in ound healing was
observed (i.e., IL-6, IL-1β, CYP1B1, CXCL1, CCL18, and KAP 4-2).
Pharmaceuticals 2020, 13, 138 6 of 12
Heise et al. performed a randomized, controlled 14 day in vivo study to compare the effects
of a 5% dexpanthenol-containing ointment with petroleum jelly on wound healing after fractional
ablative CO2 laser treatment of photo-damaged skin [2]. In total, 38 patients participated in the study.
In each patient, the wound surface was divided in two parts following laser treatment. One part was
treated with the dexpanthenol-containing ointment and one area was treated with petroleum jelly for
a duration of 7 days. In the first days of treatment, the topical use of dexpanthenol was associated
with faster wound healing than with petroleum jelly. Specifically, on days 1 and 2, lesions treated
with the dexpanthenol-containing ointment showed a significantly smaller diameter compared to
the original diameter than lesions treated with petroleum jelly (Figure 2). Similarly, the degree of
re-epithelialization was significantly greater in wounds topically treated with dexpanthenol on days 1,
2, and 5 (Figure 3), as were visual analog scale (VAS) scores for cosmetic appearance.
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Figure 2. Change of the diameter of the individual lesions between study visits. The diameter of
10 point lesions was etermined immediately after laser therapy a d mean diameter was set to 100%
and used for standardization. Data show mean ± standard deviation with n = 38, * p < 0.05, ** p < 0.01
(Mann–Whitney U test); ns: not significant. From Ref. [2] reprinted with permission of Informa UK
Limited, trading as Taylor & Francis Group (www.tandfonline.com).
Another prospective, investigator-blinded, intra-individual comparison study investigated the
effects of two 5% dexpanthenol water-in-oil formulations (ointment and emulsion) on freshly tattooed
skin in healthy subjects having received two new tattoos of comparable size [34]. The dexpanthenol
formulations were applied 4–8 times daily for 14 days, starting at 4 h after the tattooing session. Primary
outcome variable was change in transepidermal water loss (TEWL) over time. A reduction of TEWL
reflects improvement in skin barrier function, which is primarily located in the stratum corneum [65,66].
In total, 54 subjects underwent repeated TEWL measurements. The tattooing procedure induced a
7-fold increase in mean TEWL (i.e., a significant barrier dysfunction). The topical use of both 5%
dexpanthenol water-in-oil formulations was associated with a pronounced reduction in TEWL over
the study period without apparent differences between formulations. Table 1 and Figure 4 show the
results for the ointment. With both formulations, there was a virtually complete restoration of skin
barrier function after 14 days of treatment which was 1 week earlier than previously reported for
untreated sodium dodecylsulfate solution (SDS) challenged skin [16]. This is noteworthy because
tattooing is more traumatic to the skin than topical application of a skin irritant (SDS). In all subjects, an
uncomplicated healing process was observed and postprocedure cosmetic performances were highly
rated by study participants.
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Figure 3. Visual changes of the wound healing between study visits. The wound healing rates were
visually assessed, based on the measure of re-epithelialization. Data show mean ± standard deviation
with n = 38, * p < 0.05, ** p < 0.01 (Mann–Whitney U test); ns: not significant. From Ref. [2] reprinted
with permission of Informa UK Limited, trading as Taylor & Francis Group (www.tandfonline.com).
Table 1. Mean change from baseline in transepidermal water loss (TEWL) following application of 5%
dexpanthenol-containing ointment on freshly tattooed skin –8 times daily over 14 days *.
Time Change of TEWL p-Value #
Day 1 (BL) 79.14 ± 15.98 -
Day 1 (1 h after BL) −12.99 ± 19.25 0.001
Day 2 −26.16 ± 25.30 <0.001
Day 7 −60.23 ± 17.35 <0.001
Day 14 −62.62 ± 18.39 <0.001
n = 54. Data are given in g/m2/h. All values are presented as mean ± standard deviation. BL = Baseline
assessment = Mean TEWL value at approximately 4 h after the tattooing session and immediately before first
application of the ointment. TEWL = transepidermal water loss. * modified from Ref. [34]. # Dunnett’s two-tailed
t-test for change from baseline.
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occlusive wound management [67]. It can therefore be inferred that an ointment is a suitable and still 
modern galenical formulation for postprocedure wound healing. 
Historically, a 5% dexpanthenol-containing ointment has been used by tattooists in the 
postprocedure wound care despite the fact that supporting studies in this setting were lacking for 
many years [68]. Recently, clinical data were generated which provide scientific evidence for the use 
of a 5% dexpanthenol ointment in the wound aftercare of freshly tattooed skin [34]. For the wound 
care following ablative laser treatments of the skin, petroleum jelly is currently recommended by the 
manufacturers of ablative laser systems until encrustation of the affected skin area decreases [2]. 
However, petroleum jelly is a wax-like, difficult-to-handle material, particularly when larger skin 
areas have to be covered [69]. In addition, petroleum jelly has rather strong occlusive effects following 
topical application. In fact, it is used as positive reference product when the occlusion properties of 
new topical galenical developments are studied [69]. Results from a recent head-to-head comparative 
trial provided evidence that a 5% dexpanthenol-containing ointment is superior to petroleum jelly in 
the wound care after fractional ablative laser treatment as reflected by a faster wound closure and 
higher re-epithelialization rate as well as better cosmetic outcomes [2]. 
Today, different topical dexpanthenol formulations exist (cream, emollient, drops, gel, lotion, 
oil, ointment, solution, spray), developed to meet individual requirements [9]. There is cumulative 
evidence, that out of this product range, the ointment is a suitable option for postprocedure wound 
care. 
4.4. Future Perspectives 
With the availability of new treatment techniques, it can be expected that in the near future, there 
will be an increased need for postprocedural care of superficial/minor wounds and thus topical semi-
occlusive formulations accelerating re-epithelialization and healing of the injured skin. Particularly 
. ea 95% confidence i terval) ll i i l i
f l t tt s i 4–8 ti es daily for 14 days. =
t at ap roximately 4 h after the tattooing session and imme iately before treatment initiation.
TEWL = transepidermal water loss. From Ref. [34] with kind permission from Wounds International
(www.w undsinternational.com).
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4.3. Role of Galenic Composition on Postprocedure Wound Healing
Procedures resulting in superficial/minor wounds require an appropriate aftercare to assure
expedited re-epithelialization and low infection risk [1,2]. In this setting, ointments are frequently
utilized. They form a semi-occlusive breathable film that protects the wound from external influences
(e.g., pathogens or contaminants), keeps the injured area hydrated but avoids moisture congestion,
and supports a successful skin barrier restoration [1,24]. For the care of epidermal wounds, an air
interface and appropriate partial pressure of oxygen are considered important for achieving rapid
re-epithelialization [22,67]. It has been suggested that semi-occlusion of epidermal injuries results in
a superior epidermal response and an earlier achievement of skin barrier function compared to an
occlusive wound management [67]. It can therefore be inferred that an ointment is a suitable and still
modern galenical formulation for postprocedure wound healing.
Historically, a 5% dexpanthenol-containing ointment has been used by tattooists in the
postprocedure wound care despite the fact that supporting studies in this setting were lacking
for many years [68]. Recently, clinical data were generated which provide scientific evidence for the
use of a 5% dexpanthenol ointment in the wound aftercare of freshly tattooed skin [34]. For the wound
care following ablative laser treatments of the skin, petroleum jelly is currently recommended by
the manufacturers of ablative laser systems until encrustation of the affected skin area decreases [2].
However, petroleum jelly is a wax-like, difficult-to-handle material, particularly when larger skin
areas have to be covered [69]. In addition, petroleum jelly has rather strong occlusive effects following
topical application. In fact, it is used as positive reference product when the occlusion properties of
new topical galenical developments are studied [69]. Results from a recent head-to-head comparative
trial provided evidence that a 5% dexpanthenol-containing ointment is superior to petroleum jelly
in the wound care after fractional ablative laser treatment as reflected by a faster wound closure and
higher re-epithelialization rate as well as better cosmetic outcomes [2].
Today, different topical dexpanthenol formulations exist (cream, emollient, drops, gel, lotion,
oil, ointment, solution, spray), developed to meet individual requirements [9]. There is cumulative
evidence, that out of this product range, the ointment is a suitable option for postprocedure wound care.
4.4. Future Perspectives
With the availability of new treatment techniques, it can be expected that in the near future,
there will be an increased need for postprocedural care of superficial/minor wounds and thus
topical semi-occlusive formulations accelerating re-epithelialization and healing of the injured skin.
Particularly the recent insights in the potential of skin treatments with innovative lasers opened the
door for a variety of avenues to be pursued [25]. Apart from the use of ablative lasers in the treatment
of UV-damaged, pre-cancerous skin areas (e.g., actinic keratosis), promising results have been obtained
in the treatment of subjects with severely wrinkled skin [25], advanced photoaging of the face [70], and
atrophic scars [71,72]. Ablative lasers might also be beneficial for the therapy of severe rhinophyma [73],
burn scars [74], and other conditions. This type of treatment concept could also be extended to other
epithelia, such as affected mucosal membranes (e.g., leukoplakia) [25]. It has been suggested that the
temporary opening of the epidermal barrier reflects one of the greatest potentials of ablative fractional
lasers [25]. With this concept, there is the opportunity for a simplified and intensified delivery of
compounds into the dermis and epidermis. Further research is ongoing in this field.
5. Conclusions
Medical and cosmetic interventions resulting in superficial or minor wounds require appropriate
aftercare to prevent complications in wound healing (e.g., infection or scar formation) and to restore
skin integrity with an appearance and functionality which ideally is indistinguishable from the
preinjury skin. Particularly, an expedited re-epithelialization and restoration of skin barrier function are
considered key for an uneventful healing process. In this setting, ointments forming a semi-occlusive
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breathable film and providing a moist wound environment facilitate healing. Cumulative evidence
from various in vitro and in vivo studies provided scientific evidence that a dexpanthenol-containing
ointment is—beyond the care of everyday wounds—a suitable option for postprocedure wound care.
With the availability of novel skin models, new insights could be gained on the way dexpanthenol
influences the healing process of epidermal wounds at the molecular level. Gene expression data
from in vitro studies using the 3D skin model suggest that dexpanthenol upregulates genes that are
critical for wound healing. Gene expression data gathered with the 3D skin model showed good
correlations with gene expression profiles observed in in vivo studies with dexpanthenol. Moreover,
the gene expression data from both in vitro and in vivo studies are of clinical relevance as evidenced
by prospective clinical studies indicating that dexpanthenol promotes wound healing with rapid
re-epithelialization and restoration of skin barrier function following skin injury. In a comparative
study in the setting of fractional ablative laser treatment, the dexpanthenol-containing ointment
revealed superior re-epithelialization rates and better cosmetic outcomes in comparison with standard
treatment (petroleum jelly). It can therefore be concluded that topical dexpanthenol represents an
appropriate and modern treatment option for postprocedure wounds, especially when applied early
after the superficial skin damage.
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